| Name | Cizzle Biotechnology Holdings |
|---|---|
| Epic | CIZ |
| Isin | GB00BNG2VN02 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 1.96p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £7.77 | Debt ratio | n/a |
| Shares in issue | 396.39 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -171.96 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -0.3 | 52-week high / low | 1.45p / 2.60p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Cizzle Biotechnology Holdings |
|---|---|
| Address | 6th Floor, 60 Gracechurch Street, London, United Kingdom, EC3V 0HR |
| Telephone | +44 (0)20 7264 4444 |
| Website | http://www.cizzlebiotechnology.com |
| Director | Position |
|---|---|
| Mr Nigel Ronald Lee | Finance Director |
| Mr Dawn Alison Coverley | Non-Executive Director |
| Mr Allan John Syms | Executive Chairman |
| Mr John Treacy | Independent Non-Executive Director |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | 2.08 | 0.2 | n/a |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 2.08 | 0.2 | n/a |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 0.23 | 0.08 | 0 |
| Cash and equivalents | 0.48 | 0.88 | 0.01 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 2.79 | 1.16 | 0.01 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 0.15 | 0.22 | 0.02 |
| Long term liabilities | n/a | n/a | n/a |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 0.14 | 0.22 | 0.02 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 2.64 | 0.94 | -0.01 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 3.5 | 3.49 | n/a |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -6.15 | -5.52 | -1.6 |
| Share premium account | 34.92 | 32.57 | 1.58 |
| Total equity | 2.64 | 0.94 | -0.01 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -0.96 | -3.96 | -0.01 |
| Pre-tax profit | -0.96 | -3.96 | -0.01 |